Claire completed her bachelor’s and master’s degree in pharmaceutical sciences at KU Leuven (Belgium). Additionally, she holds a master’s degree in drug development at KU Leuven, in which she did part of her study at Université Paris Descartes in France. Claire’s project within the THERADNET network focuses on the impact of hypofractionated radiotherapy treatment regimens on tumor hypoxia and tumor acidification. More specifically, she will be investigating the role of a specific survival kinase which becomes activated in hypoxic areas and areas under stress which slows down tumor cell proliferation. Inhibiting this kinase might give rise to a novel combined treatment modality with irradiation. Furthermore, her project also will reveal how radiotherapy treatment regimens affect tumor acidification and thereby suppress tumor immune response.